Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	419.31M
Revenue (ttm)	160.40M
Net Income (ttm)	-62.64M
Shares Out	27.09M
EPS (ttm)	-2.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	610,101
Open	14.70
Previous Close	14.84
Day's Range	14.68 - 15.80
52-Week Range	14.30 - 45.00
Beta	2.63
Analysts	Strong Buy
Price Target	65.00 (+319.9%)
Earnings Date	Nov 7, 2024

About ARCT

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 180
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT
• Website: https://arcturusrx.com

Analyst Forecast

According to 7 analysts, the average rating for ARCT stock is "Strong Buy." The 12-month stock price forecast is $65.0, which is an increase of 319.90% from the latest price.

Price Target

$65.0

(319.90% upside)

Analyst Consensus: Strong Buy